Herpes simplex virus: Difference between revisions

From IDWiki
(created outline)
(Initial completion of background section)
Line 1: Line 1:
  +
* Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the [[Human herpesvirus]] family
  +
* Cause typical painful vesicular lesions on labia or external genitals
  +
* Occasionally cause a viral encephalitis
  +
 
== Background ==
 
== Background ==
   
 
=== Microbiology ===
 
=== Microbiology ===
* Double-stranded DNA virus
+
* Enveloped, double-stranded DNA virus
  +
* HSV-1 and HSV-2 are morphologically and genetically distinct viruses
  +
* Can be infected with both
   
 
=== Epidemiology ===
 
=== Epidemiology ===
  +
* Worldwide distribution, and only found in humans
  +
* Most common cause of genital lesions
  +
* Spread through person-to-person contact with skin or mucosa; not spread via fomits
  +
* HSV-1 is more common, with 90% of adults having antibodies by age 40
  +
** Often acquired in childhood in Asia and Africa
  +
** More common in lower SES populations
  +
* HSV-2 has seroprevalence of 15-20% in US
  +
** More common in women than men, in HIV-infected people, and in MSM
  +
** May be subclinical if already infected with HSV-1
   
 
=== Pathophysiology ===
 
=== Pathophysiology ===
  +
* Fusion of envelope and cell membrane is mediated by viral glycoproteins B, C, and D and host cell proteins cellular heparin sulfate, TNF receptors, and immunoglobulins
  +
* Internal capsid is released, which makes its way to the nucleus
  +
* Viral DNA polymerase enzyme and viral DNA helicase are targets of antivirals
  +
* Viral DNA may remain latent in about 10% of nearby neurons, characterized by latency-associated transcripts (LATs)
  +
** Despite being latent, virus can still be shed in mucosa anywhere from 1/10 to 3/4 of days
  +
* HSV-1 prefers trigeminal ganglia as well as cervical ganglia, or sacral nerve root ganglia if genital
   
 
== Clinical Presentation ==
 
== Clinical Presentation ==
  +
* Incubation period usually within 5 days for primary infection
   
 
== Diagnosis ==
 
== Diagnosis ==

Revision as of 11:32, 16 October 2019

  • Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the Human herpesvirus family
  • Cause typical painful vesicular lesions on labia or external genitals
  • Occasionally cause a viral encephalitis

Background

Microbiology

  • Enveloped, double-stranded DNA virus
  • HSV-1 and HSV-2 are morphologically and genetically distinct viruses
  • Can be infected with both

Epidemiology

  • Worldwide distribution, and only found in humans
  • Most common cause of genital lesions
  • Spread through person-to-person contact with skin or mucosa; not spread via fomits
  • HSV-1 is more common, with 90% of adults having antibodies by age 40
    • Often acquired in childhood in Asia and Africa
    • More common in lower SES populations
  • HSV-2 has seroprevalence of 15-20% in US
    • More common in women than men, in HIV-infected people, and in MSM
    • May be subclinical if already infected with HSV-1

Pathophysiology

  • Fusion of envelope and cell membrane is mediated by viral glycoproteins B, C, and D and host cell proteins cellular heparin sulfate, TNF receptors, and immunoglobulins
  • Internal capsid is released, which makes its way to the nucleus
  • Viral DNA polymerase enzyme and viral DNA helicase are targets of antivirals
  • Viral DNA may remain latent in about 10% of nearby neurons, characterized by latency-associated transcripts (LATs)
    • Despite being latent, virus can still be shed in mucosa anywhere from 1/10 to 3/4 of days
  • HSV-1 prefers trigeminal ganglia as well as cervical ganglia, or sacral nerve root ganglia if genital

Clinical Presentation

  • Incubation period usually within 5 days for primary infection

Diagnosis

Management

References

  1. a b  M. Howard, J. W. Sellors, D. Jang, N. J. Robinson, M. Fearon, J. Kaczorowski, M. Chernesky. Regional Distribution of Antibodies to Herpes Simplex Virus Type 1 (HSV-1) and HSV-2 in Men and Women in Ontario, Canada. Journal of Clinical Microbiology. 2003;41(1):84-89. doi:10.1128/jcm.41.1.84-89.2003.